The purpose of this study was to identify the population prevalence across the stages of change (SoC) for regular physical activity and to establish the prevalence of people at risk. With support from the National Institutes of Health, the American Heart Association, and the Robert Wood Johnson Foundation, nine Behavior Change Consortium studies with a common physical activity SoC measure agreed to collaborate and share data. The distribution pattern identified in these predominantly reactively recruited studies was Precontemplation (PC) = 5% (+/- 10), Contemplation (C) = 10% (+/- 10), Preparation (P) = 40% (+/- 10), Action = 10% (+/- 10), and Maintenance = 35% (+/- 10). With reactively recruited studies, it can be anticipated that there will be a higher percentage of the sample that is ready to change and a greater percentage of currently active people compared to random representative samples. The at-risk stage distribution (i.e., those not at criteria or PC, C, and P) was approximately 10% PC, 20% C, and 70% P in specific samples and approximately 20% PC, 10% C, and 70% P in the clinical samples. Knowing SoC heuristics can inform public health practitioners and policymakers about the population's motivation for physical activity, help track changes over time, and assist in the allocation of resources.

Twenty-three patients (61%) had progressive disease and 15 patients (39%) had no response or a partial response at the conclusion of salvage chemotherapy. Twenty-two patients (58%) underwent high dose chemotherapy and proceeded to HDT and ASCT. The percentage of patients that underwent ASCT who received accelerated fractionated SRT compared to conventionally fractionated SRT was not statistically different (59% vs 56%, pZ0.86). Accelerated fractionation compared to conventional fractionation was associated with a significant improvement in complete response (CR) rate (86% vs 50%, pZ0.015) and 2-year disease free survival (59% vs 19%, pZ0.031). There was a trend towards a significant improvement in 2-year loco-regional control (82% vs 56%, pZ0.052); however, 2-year overall survival (59% vs 63%, pZ0.96) was not significantly different. Conclusion: In patients with DLBCL who were refractory to salvage chemotherapy, the use of salvage radiation therapy was associated with a high rate of conversion to ASCT eligibility in a group of patients that are frequently ineligible for ASCT. The use of accelerated fractionation compared to conventional fractionation SRT was associated with a significantly improve CR rate and DFS. Prospective trials are needed to further identify the patients that would derive the most benefit from accelerated fractionated SRT in this setting.

Median copy number per mL was 41.7 in the total cohort, 1054.2 (range 17.5-161083.3) in OPX, 479.2 (range 22.9-38500.0) in AC, and 39.2 (range 12.9-39666.7) in UC patients. There was no association between ctHPVDNA detectability and age at diagnosis, sex, smoking history, T stage, N stage, or M stage. Among patients with cervical cancer, ctHPVDNA was detectable in 80% of patients with squamous or adenosquamous histology vs 25% of patients with adenocarcinoma (p Z 0.0314). The median follow-up for all patients was 27 months (IQR 17.9-34.3 months). Recurrence at any site occurred in 14 of 71 patients (19.7%). Compared to patients with undetectable ctHPVDNA, detectable ctHPVDNA was not associated with disease recurrence (hazard ratio 0.925, 95% CI 0.266-3.217, p Z 0.902). There was no association between ctHPVDNA copy number and recurrence when stratifying by <200 copies per mL versus >200 copies per mL. Conclusion: We demonstrate the feasibility of pre-treatment ctHPVDNA detectability in patients with squamous or adenosquamous carcinoma of the oropharynx, anal canal, and uterine cervix. This is the first validation of a ctHPVDNA assay in anal canal and cervical cancer. Further investigation of ctHPVDNA levels pre-treatment, post-treatment, and during surveillance in these malignancies is warranted.

No abstract

No abstract